Ignite Creation Date:
2025-12-25 @ 2:44 AM
Ignite Modification Date:
2025-12-31 @ 11:16 AM
Study NCT ID:
NCT04206033
Status:
COMPLETED
Last Update Posted:
2021-07-27
First Post:
2019-12-18
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Hemophilia and Bone Metabolism: Study of Monocytic Populations and Inflammatory Proteins
Sponsor:
Nantes University Hospital
Organization:
Study Overview
Official Title:
Hemophilia and Bone Metabolism: Study of Monocytic Populations and Inflammatory Proteins
Status:
COMPLETED
Status Verified Date:
2021-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BOHEM
Brief Summary:
The investigators propose, as part of the study, to carry out for each patient:
* An analysis of monocytic populations by flow cytometry (CD14, CD16, CD45, CD68, CD115, CCR2, CX3CR1, CD163 and CD206).
* A population assessment of Myeloid-Derived Suppressor Cells (MDSC).
* Assays of cytokines and chemokines involved in inflammation by multiplex analyzes: Il-1 (α and β), Il-4, Il-6, Il-10, Il-13, TNF- α, TGF- β, CRP , leptin, IFN- β.
* Specialized dosages of proteins involved in bone metabolism. RANKL, osteoprotegerin, M-CSF, TRAPCP5.
* An analysis of monocytic populations by flow cytometry (CD14, CD16, CD45, CD68, CD115, CCR2, CX3CR1, CD163 and CD206).
* A population assessment of Myeloid-Derived Suppressor Cells (MDSC).
* Assays of cytokines and chemokines involved in inflammation by multiplex analyzes: Il-1 (α and β), Il-4, Il-6, Il-10, Il-13, TNF- α, TGF- β, CRP , leptin, IFN- β.
* Specialized dosages of proteins involved in bone metabolism. RANKL, osteoprotegerin, M-CSF, TRAPCP5.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: